UNITY Biotechnology declares positive data from phase 1 clinical trial of UBX1325 in Advanced Vascular Eye Disease patients
UNITY Biotechnology, Inc., a biotechnology company developing therapeutics to decrease, impede, or reverse diseases of aging, declared positive data from its Phase 1 safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) for whom anti-VEGF therapy was no longer considered useful. UBX1325, a small molecule inhibitor of Bcl-xL and the first senolytic therapeutic assessed in an ophthalmological clinical study, was well-tolerated with no treatment-related...
